SeromYx Systems, Inc. Appoints Andrew Ball, PhD, as Chief Executive Officer

Abigail Harris • February 5, 2025

Download PDF

Woburn, MA, February 5th, 2025 — SeromYx Systems, Inc. , a global leader in high-throughput antibody characterization and Systems Serology services, today announced the retirement of Chief Executive Officer, Mr. Piers Whitehead, a co-founder of the company, who will remain with the organization as a member of the Board of Directors and as a strategic advisor. Concurrently, as part of a planned transition, Andrew Ball, PhD has been appointed Chief Executive Officer and Director, effective February 4th, 2025.

Dr. Ball brings over 20 years of global leadership experience in the life sciences industry, with a successful track record in technical and commercial development of assay platforms and services. Most recently, he served as Vice President, Assay Development Platforms at Abcam, a Danaher company, where he led a global R&D organization developing and commercializing immunoassays, cell-based assays, antibody conjugates, recombinant proteins and contract assay services. He has also held roles as VP of Assay Development at Quanterix, developing ultrasensitive assays for neurodegenerative disease and immunooncology; as VP of R&D at Quad Technologies, a cell and gene therapy startup acquired by Bio-Techne, and has served in a variety of innovation and strategic leadership roles at MilliporeSigma.

Commenting on the appointment, Armin Spura, PhD, Executive Chairman of the Board of Directors said:

“On behalf of the Board, I want to thank Piers for his many contributions to SeromYx’s success since its founding. Under Piers’ leadership, SeromYx has grown to become successful and profitable, powered by the leading technology platform for Fc effector profiling. I am very pleased to announce the appointment of Dr. Andrew Ball as our new Chief Executive Officer. Andrew is a distinguished industry leader whose deep experience in assay development, insights into antibody development, and ability to bridge technical and commercial applications make him the ideal choice to lead SeromYx. We are confident that Andrew’s vision and strategic acumen will position SeromYx for continued success in the years ahead.”

Andrew Ball added:

“ I am excited to join SeromYx at this pivotal time as we continue to deliver for our clients and build on the strong foundations the company has established – with our comprehensive Fc effector function profiling platform. I believe SeromYx is uniquely positioned to deliver new insights into the correlation between function and clinical outcomes during therapeutic antibody discovery and development. “

The company extends its gratitude to Piers Whitehead for his leadership and contributions, which have positioned SeromYx for continued success.

About SeromYx Systems, Inc.:
SeromYx Systems, Inc. is a global leader in providing GCLP high-throughput antibody characterization and Systems Serology services, offering advanced solutions for the comprehensive analysis of immune responses and correlation of antibody function with clinical outcomes. With a dedication to innovation and excellence, SeromYx is at the forefront of revolutionizing the field of vaccine and therapeutic antibody development through its cutting-edge technologies and strategic collaborations.

Contact:
Abigail Harris
Business Development Manager
Abigail.harris@seromyx.com

Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria

November 20, 2025
The Fc Review: One Fc variant, three advantages? A Nature Communications study demonstrates how a single Fc-engineered IgG achieved improved half-life, mucosal distribution, and enhanced immune-mediated killing, across both cancer and bacterial models. Background: Fc engineering is often discussed through a single lens, half-life extension, effector boosting, or silencing. This paper explores a broader question: can an Fc variant containing three point mutations deliver multiple functional gains across different biological systems?

Design and engineering of bispecific antibodies: insights and practical considerations

October 28, 2025
The Fc Review: How does Fc engineering shape bispecific antibody function? A Frontiers in Bioengineering and Biotechnology review explores how the Fc region can be tuned to control effector function, half-life, and safety, key levers in the design of next-generation bispecific antibodies ( bsAbs ). Background: Bispecific antibodies bring new therapeutic possibilities by engaging multiple targets at once. But this complexity also brings new challenges, from unwanted immune activation to altered pharmacokinetics . The Fc region plays a central role here, acting as both a stabilizing scaffold and a regulator of immune effector engagement

An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer

October 23, 2025
Abstract: Fc engineering to enhance antibody effector functions harbors the potential to improve therapeutic effects. Understanding FcγR expression and distribution in the tumor microenvironment prior to and following treatment may help guide immune-engaging antibody design and patient stratification. In this study, we investigated FcR-expressing immune effector cells in HER2 + and triple-negative breast cancers (TNBC), including neoadjuvant chemotherapy–resistant disease. FcγRIIIa expression, FcγRIIIa + NK cells, and classically activated (M1-like) macrophages correlated with improved anti-HER2 antibody efficacy. FcγRIIIa protein and FcγRIIIa + NK cells and macrophages were present in primary TNBC and retained in treatment-resistant tumors.
Text:

Antibody Engineering and Therapeutics 2025

October 10, 2025
Antibody Engineering & Therapeutics 2025

Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial

September 15, 2025
Background Authorized COVID-19 vaccines require boosters for continued protection; however, the lack of crossplatform compatible boosters creates practical challenges to keeping populations protected. Methods This Phase 3, multicenter, international, randomized, active-controlled trial compared UB-612 as a thirddose heterologous booster to BNT162b2, ChAdOx1-S, or BBIBP-CorV homologous boosters in healthy subjects aged ≥16 years. Participants were randomly assigned 1:1 to receive a single intramuscular injection of UB-612 or an active comparator matching the primary dose, and were stratified for age, sex, N-protein seropositivity, and time since the last dose of their primary series COVID-19 vaccination. The primary objective was to show noninferiority of neutralizing antibody geometric mean titer (GMT) against live SARS-CoV-2 Wuhan strain after boosting with UB-612 or each of the licensed platform vaccines. Secondary and exploratory objectives covered short and long-term antibody responses. The safety analysis addressed subject and investigator reported adverse events. The study was registered on ClinicalTrials.gov, NCT05293665, and completed on September 12, 2023.

Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies

September 9, 2025
The Fc Review: Continuing our series taking a closer look at recent Fc-focused papers, what they found, and why it matters for antibody discovery and development. How does Fc engineering shape the translation of antibodies from preclinical models to the clinic? A new industry-wide review with 15 case studies examines the impact of Fc modifications on pharmacology and safety, and the challenges of predicting human outcomes from nonclinical studies. Background: Fc regions do not only extend half-life, they drive functions like ADCC , ADCP, CDC, and immune modulation. Engineering the Fc can enhance, silence, or redirect these activities. But the same changes that deliver potency can also introduce risk, especially when preclinical models do not fully mirror human Fc receptor biology.

NextGen Biomed 2026

August 25, 2025
NextGen Biomed 2026

Fc gamma receptor polymorphisms in antibody therapy: implications for bioassay development to enhance product quality

August 13, 2025
The Fc Review: Kicking off a new series where we take a closer look at recent Fc-focused papers. What they found, and why it matters for antibody discovery and development. How much does FcγR genetic variation influence an antibody’s function? A recent FDA review examines the often-overlooked role of Fcγ receptor (FcγR) polymorphisms in shaping therapeutic antibody activity, and the implications for the assays used to measure it. Background: FcγRs are the “effector arm” connection between antibodies and immune cells, driving processes like ADCC and ADCP. Genetic variation in these receptors can alter binding strength, modulate effector function, and impact clinical outcomes. Understanding this interplay is important for therapeutic design, potency assessment, and patient response prediction.

Analysis of Fc-dependent effector functions of anti-malaria circumsporozoite protein antibodies

July 23, 2025
Journal Abstract: Antibodies targeting the malaria circumsporozoite protein (CSP) can prophylactically protect against malaria by targeting Plasmodium parasites before they establish symptomatic blood-stage disease. Engineering the antibody Fc region to more effectively engage immune effector functions has produced therapeutic antibodies with enhanced potency against viral and oncological targets. However, whether Fc-dependent immune effector functions can contribute to the protection of malaria CSP mAbs or be further enhanced via engineering has been limitedly tested. Here, we report that Fc-dependent effector functions are required for achieving maximal protection via prophylactic treatment with the CSP mAb 317. We further report that Fc engineering modulated the activity of multiple CSP mAbs in multiple in vitro assays of effector function. Our studies revealed that the mAbs L9 and CIS43 were more potent drivers of antibody-dependent phagocytosis, NK activation and killing, and complement deposition. In contrast, 317, but not L9 and CIS43, drove enhanced activation of CSP-responsive T-cells after DC acquisition of mAb-complexed antigens. Collectively, our data suggest that effector function represents an important mechanism of anti-CSP antibodies with the potential to enhance activity through Fc engineering.

The Fc-Mediated Effector Function Summit

June 1, 2025
The Fc-Mediated Effector Function Summit
More Posts →